Ann: Appendix 4C - quarterly, page-3

Pretty happy. Not a lot to go on just yet as we will get more info in the half yearly.

Wonderful to see our cash balance more than double in the quarter to $1.5 million on ZinClear sales alone. The R&D credit will further bolster cash levels next quarter so we should maintain and continue to grow a strong war chest of cash - >$2-2.5m+ is easily achieveable.

Based on their growth on prior corresponding half we can expect ZinClear revenue to be about $2.25 million for the current half - which is more than the entire total revenue for 1H16! Just incredible. As forecasted, we are on target to hit ~$5m ZinClear sales for the full year as we continue to grow at these double digit rates.

Once we add in the Merck revenue in 2H17, we should end the year in a very strong cash and profit position - a nice dividend is almost a given.

It is a GREAT time to be a shareholder. Congratulations to those who got in today prior to the release - couldn't have timed it better.